MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer.

Matias A BustosTakamichi YokoeYoshiaki ShojiYuta KobayashiShodai MizunoTomohiro MurakamiXiaoqing ZhangSreeja C SekharSooMin KimSuyeon RyuMatthew KnarrSteven A VasilevAnalisa DiFeoRonny DrapkinDave S B Hoon

Published in: Cell & bioscience (2023)

miR-181a is a key factor controlling the STING pathway and driving PARPi and platinum-based drug resistance in TNBC and OvCa. The miR-181a-STING axis can be used as a potential marker for predicting PARPi responses in TNBC and OvCa tumors.

Keyphrases

cell proliferation
long non coding rna
long noncoding rna
dna repair
oxidative stress
risk assessment